Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of IV Eptinezumab in Adolescents (12-17 Years) for the Preventive Treatment of Chronic Migraine

NCT04965675 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT04965675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04965675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of IV Eptinezumab in Adolescents (12-17 Years) for the Preventive Treatment of Chronic Migraine
Lead sponsor
H. Lundbeck A/S
Phase
Phase 3
Overall status
Recruiting
Start date
June 30, 2021
Completion date
October 31, 2026
Enrollment
285 (estimated)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

chronic migraine in children